Voriconazole

伏立康唑

Report date: 2026/05/24 20:00:34
NME

Base Information

Drug NameVoriconazole
Drug Alias NameVoriconazolum伏力康唑优立康唑威凡Vfend +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLanosterol 14α-demethylase inhibitors
TargetsLanosterol 14α-demethylase
Therapy Area/IndicationsImmunologic Deficiency SyndromesGraft vs Host DiseaseNeutropenia +[28] 
Global Approved IndicationsFusariosisCryptococcosisCandidiasis +[5] 
Approved Indications in ChinaMycoses
Original Approved Country/TerritoryEU
Original Approved Date2002/03/19
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesHikmaPfizer IncPostgraduate Institute Of Medical Education And Research +[8] 
Inactive CompaniesUniversity Of California San FranciscoEunice Kennedy Shriver National Institute Of Child Health And Human DevelopmentMasonic Cancer Center, University Of Minnesota +[10] 
Active IndicationsFusariosisCryptococcosisCandidemia +[8] 
Inactive IndicationsImmunologic Deficiency SyndromesGraft vs Host DiseaseNeutropenia +[20] 

Other Information

ATC CodeJ02AC03
Related LinksWikipediaDrugBankKEGG